Výsledky vyhledávání - "Jefferson Ruiz"

Akademický článek

Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review

Autor: Marco Aurélio Salvino, Jefferson Ruiz

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 38, Iss 1, Pp 28-36 (2016)

ABSTRACT The use of high-dose chemotherapy with autologous support of hematopoietic progenitor cells is an effective strategy to treat various hematologic neoplasms, such as non-Hodgkin lymphomas and multiple myeloma. Mobilized peripheral blood proge

Externí odkaz: https://doaj.org/article/a6d372bdf330473190251d3b27df911a

Zobrazit plný text záznamu

Akademický článek

Allogeneic bone marrow transplantation for severe aplastic anemia patients with risk factors for poor prognosis: is fludarabine a requirement? Transplante alogênico de medula óssea em portadores de anemia aplásica severa com fatores de mau prognóstico: é necessário fludarabina?

Autor: Carlos R. de Medeiros, Elenaide Coutinho, Eliane R. Carmes, Marco A. Bitencourt, Jefferson Ruiz, Carmen S. Bonfim, Vaneusa M. Funke, Daniela C. Setubal, José Zanis-Neto, Ricardo Pasquini

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 30, Iss 4, Pp 292-296 (2008)

Hematopoietic progenitor cell transplantation from HLA-identical sibling donors cures 70-90% of Severe Aplastic Anemia (sAA) patients. Older age, heavy exposure to transfusions, immunosuppression treatment (IST) with a long interval from diagnosis to

Externí odkaz: https://doaj.org/article/e378f5e5db8e44fbaeb76679c6ad2910

Zobrazit plný text záznamu

Akademický článek

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate

Autor: Vaneuza M. Funke, Daniela C. Setubal, Jefferson Ruiz, Ana Paula Azambuja, Denise H. Lima, Terezinha K. Kojo, Ricardo Pasquini

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 30, Pp 27-31 (2008)

O mesilato de imatinibe é atualmente o tratamento de escolha para pacientes com Leucemia mielóide Crônica (LMC) recém-diagnosticados. Desde os primeiros estudos clínicos em 1998 até o estudo IRIS, que comparou o uso em primeira linha de imatini

Externí odkaz: https://doaj.org/article/036e5b32ce7c4cfba8b09d40bdb13199

Zobrazit plný text záznamu

Akademický článek

Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases Tratamento da leucemia mielóide crônica com imatinib mesilato no Brasil: estudo de 98 casos

Autor: Vaneuza A. M. Funke, Carlos R. Medeiro, Denise H. Lima, Daniela C. Setúbal, Marco A. Bitencourt, Carmem M. Bonfim, Jefferson Ruiz, José Zanis Neto, Ricardo Pasquini

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 27, Iss 3, Pp 159-165 (2005)

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 (Philadelphia chromosome). The resulting BCR-ABL gene has tyrosine kinase activity which stimulates cellular growth. Imatinib mesy

Externí odkaz: https://doaj.org/article/82f19a747fe242d9856787232f40205b

Zobrazit plný text záznamu

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response in Newly Diagnosed Chronic-phase cronic Myeloid Leukemia in Brasil: 24-months follow-up

Autor: Marta M. Lemos, Jefferson Ruiz, J. Valentim, Marcia Dias Alves, John Coombs

Publikováno v: Blood. 118:4216-4216

Abstract 4216 Background: The use of imatinib (IM) has greatly improved the outcome of patients with Ph+ chronic myeloid leukemia (CML), with a good balance of potency and exposure that translated into clinical efficacy for many patients. However, pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bfdf721dbe1d1acf8fe427086522d47
https://doi.org/10.1182/blood.v118.21.4216.4216

Zobrazit plný text záznamu

Number Needed to Treat (NNT) and Cost Estimation to Achieve a Major Molecular Response In Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia In Brazil

Autor: Marta M. Lemos, John Coombs, Jefferson Ruiz, Marcia Dias Alves, J. Valentim

Publikováno v: Blood. 116:1520-1520

Abstract 1520 Background: The use of imatinib (IM) has greatly improved the outcome of patients with Ph+ chronic myeloid leukemia (CML), with a good balance of potency and exposure that translated into clinical efficacy for many patients. However, pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2fa32a5b77194fc238f6e2b563eccd86
https://doi.org/10.1182/blood.v116.21.1520.1520

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání